drugset
drugset / Trial / NCT00125333

Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis

NCT00125333 ↗

Phase 1/2 Completed 75 enrolled Anesiva, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether this topical NF-kappaB Decoy candidate is safe in persons with atopic dermatitis. Preliminary evidence of efficacy (whether it is working) will also be evaluated.

Timeline

Start
2005-03
Primary completion
—
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject NF-kappaB Decoy Oligonucleotide (other) — Topical

Indications

atopic eczema